Santos Esteban 4

What Happened

• Santos Esteban, EVP, Operations at Amgen, was granted equity awards on 2026-05-05: 2,730 restricted stock units (RSUs) and a derivative grant of 17,814 non-qualified stock options with an exercise price of $329.59 (grant valued at ~$5,871,316). On 2026-05-06, 427 shares were surrendered/withheld at $329.59 each to cover tax liabilities (cash value $140,735).
• These transactions are awards/grants (not open-market purchases or sales); the 427-share disposition is a routine tax withholding.

Key Details

• Transaction dates and prices:
  • 5/05/2026: RSU grant — 2,730 shares @ $0.00 (acquired).
  • 5/05/2026: Option grant (derivative) — 17,814 shares @ $329.59 (acquired; reported value ~$5,871,316).
  • 5/06/2026: Tax withholding/payment — 427 shares @ $329.59 (disposed; $140,735).
• Vesting and payout notes:
  • RSUs vest in four equal annual installments (25%/year) beginning 5/5/2027; vested RSUs paid 1-for-1 in common stock (F1).
  • 388 Dividend Equivalents (DEs) are included with the RSUs and pay out as shares per the vesting schedule (F2).
  • The option grant vests and becomes exercisable in four equal annual installments starting 5/5/2027 (F3).
• Shares owned after the transaction: not disclosed in this filing.
• Filing timeliness: Report filed 2026-05-07 for transactions dated 5/05–5/06/2026; appears timely (filed within the normal 2-business-day window).

Context

• This filing reflects equity compensation grants (standard executive awards) rather than a market purchase or a sell for investment purposes. The 427-share disposition was for tax withholding (common practice when RSUs/options are granted or vest), not an open-market sale indicating a change in investment stance.